Candel Therapeutics Q1 net loss $8.2M; highlights positive CAN-2409 pancreatic cancer survival data

Candel Therapeutics, Inc.

2024-Q1 EPS reported -$0.28

Net loss $8.2M vs $8.8M YoY; R&D expenses $4.1M, G&A $3.8M.
Cash $25.7M as of March 31, 2024; expected to fund operations into Q4 2024.
CAN-2409 pancreas phase 2: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.
Phase 2 CAN-2409 NSCLC topline OS data to be presented at ASCO on June 3, 2024.
Phase 3 CAN-2409 prostate cancer disease-free survival data expected in Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.